EARLY ADMINISTRATION OF GOS/FOS PREVENTS INTESTINAL AND RESPIRATORY INFECTIONS IN INFANTS

Раннее назначение GOS/FOS предотвращает кишечные и респираторные инфекции у младенцев
Eugenia Bruzzese, M Volpicelli, Filippo Salvini, M. Bisceglia, Paolo Lionetti, M Cinquetti, Giuseppe Iacono, Alfredo Guarino
2006-05-01

Acute diarrhoeaGOS/FOS prebioticsInfant formulaRandomised placebo-controlled trialUpper respiratory tract infections
The addition of a mixture of galacto-oligosaccharides (GOS) and fructo-oligosaccharides (FOS) to infant formula modifies the intestinal microbiota of infants, increasing the number of Bifidobacteria. However, it is not known whether this change has any clinical relevance. Because probiotics may have a preventive anti-infectious effect, we tested the hypothesis that prebiotics reduce the incidence of intestinal and respiratory infections in healthy young infants. A prospective, randomised, placebo-controlled, 12 month open trial, was performed. Healthy infants, (15 to 120 days) were randomised either to a standard formula containing GOS/FOS in a 9/1 ratio, or to a control standard formula. At enrolment and after 3, 6, 9 and 12 months the following parameters were registered: anthropometric measures, number of episodes of acute diarrhoea and of respiratory tract infections. 281 infants completed the study, 136 in the GOS/FOS group and 145 in the control group. No differences in age, weight and length were observed between the groups at the enrolment. A reduced incidence of acute diarrhoea was observed in children on GOS/FOS compared to controls (0.15±0.03 vs. 0.28±0.04 episodes/child/12 months; p < 0.01). The number of children with at least one episodes of acute diarrhoea was significantly lower in the group of infants on GOS/FOS (17 vs. 34; p <0.05). The latter also showed a slight reduction of upper respiratory tract infections (URTI). Interestingly the number of children with more than 3 episodes of URTI/year was significantly lower in the group of children receiving GOS/FOS (19 vs. 35; p < 0.05). In addition the number of children who received more than two antibiotics courses/year was significantly lower in children on GOS/FOS (30 vs. 49; p< 0.05). This is the first direct evidence that prebiotics reduce intestinal and possibly extra-intestinal infections and have therefore a clinical effect. These effects are probably due to the immune imprinting that follows microbiological imprinting in the first weeks of age.
1
A 12-month randomized, placebo-controlled trial evaluated whether infant formula supplemented with GOS/FOS prevents intestinal and respiratory infections.
2
Fewer GOS/FOS-fed infants experienced at least one acute diarrhoea episode: 17 versus 34 controls (p<0.05).
3
Fewer infants receiving GOS/FOS required more than two antibiotic courses annually: 30 versus 49 controls (p<0.05), suggesting clinical anti-infective effects.
4
GOS/FOS reduced recurrent upper respiratory tract infections, with fewer infants experiencing more than three episodes annually: 19 versus 35 (p<0.05).
5
GOS/FOS supplementation reduced acute diarrhoea incidence versus control formula: 0.15±0.03 versus 0.28±0.04 episodes per child over 12 months (p<0.01).

Healthy young infants receiving standard formula with or without a GOS/FOS prebiotic mixture

The preventive clinical effects of early GOS/FOS administration on the incidence of acute diarrhoea, respiratory tract infections, and antibiotic use

Publication Details
Publication Date
2006-05-01
Journal
Publisher
ISSN
Access Type
Author Information
Authors
Eugenia Bruzzese
M Volpicelli
Filippo Salvini
M. Bisceglia
Paolo Lionetti
M Cinquetti
Giuseppe Iacono
Alfredo Guarino
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat
Make a presentation
100%